Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Analysts Just Slashed This Year's Estimates [Yahoo! Finance]
Agios Pharmaceuticals, Inc. (AGIO)
Last agios pharmaceuticals, inc. earnings: 4/30 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.agios.com/investor-overview
Company Research
Source: Yahoo! Finance
revision to their near-term (statutory) forecasts for the organization. Both revenue and earnings per share (EPS) forecasts went under the knife, suggesting analysts have soured majorly on the business. Shares are up 5.4% to US$26.51 in the past week. Investors could be forgiven for changing their mind on the business following the downgrade; but it's not clear if the revised forecasts will lead to selling activity. After the downgrade, the nine analysts covering Agios Pharmaceuticals are now predicting revenues of US$43m in 2024. If met, this would reflect a sizeable 79% improvement in sales compared to the last 12 months. Per-share losses are expected to explode, reaching US$5.80 per share. Yet before this consensus update, the analysts had been forecasting revenues of US$71m and losses of US$5.20 per share in 2024. Ergo, there's been a clear change in sentiment, with the analysts administering a notable cut to this year's revenue estimates, while at the same time increasing their
Show less
Read more
Impact Snapshot
Event Time:
AGIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AGIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AGIO alerts
High impacting Agios Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
AGIO
News
- Agios to Webcast Conference Call of First Quarter Financial Results on May 1, 2025GlobeNewswire
- MOMA Therapeutics Appoints Susan Pandya, M.D., to Board of Directors and Expands Management Team [Yahoo! Finance]Yahoo! Finance
- Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Corporate Development & Strategy OfficerGlobeNewswire
- Agios to Present at Upcoming Investor ConferencesGlobeNewswire
- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $58.00 price target on the stock.MarketBeat
AGIO
Earnings
- 10/31/24 - Miss
AGIO
Sec Filings
- 4/10/25 - Form 4
- 4/8/25 - Form 144
- 3/7/25 - Form 4
- AGIO's page on the SEC website